Cell Biology and Toxicology

, Volume 11, Issue 5, pp 273–281 | Cite as

Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells

  • G. Chen
  • K. -J. Hutter
  • W. J. Zeller


While multiple changes are frequently found to be associated with cisplatin resistance in a variety of tumor cell lines, a cause-effect relationship of these alterations with the resistant phenotype has not been established. In order to identify the resistance-relevant determinants, a series of cisplatinresistant sublines with different degrees of resistance to cisplatin was developed in a human ovarian carcinoma cell line (O-129). Three derived resistant cell lines displayed 2.1-fold (O-129/DDP4, low), 4.1-fold (O-129/DDP8, moderate) and 6.3-fold (O-129/DDP16, high) resistance, respectively, to cisplatin, compared with the sensitive parental line O-129. While the activity of poly(ADP-ribose) polymerase, an enzyme proposed to be involved in DNA repair, was elevated in all three resistant lines, a significant karyotypic change was observed only in the high-resistance line with the karyotype alteration from near diploidy to heteroploidy. The moderate (4.1-fold) and high (6.3-fold) DDP resistance was associated with a slow proliferation rate in drug-free medium, but cellular glutathione level was highly correlated with DDP sensitivity in all four cell lines. Taken together, the present studies establish that while many changes at cellular level can occur with development of cisplatin resistance, only elevation of intracellular glutathione concentration appears to be related to the resistance phenotype in these human ovarian cancer cells.

Key words

cisplatin resistance glutathione human ovarian cancer cells 





fetal bovine serum




drug concentration required to result in 50% growth inhibition


poly(ADP-ribose) polymerase


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berger NA, Weber G, Kaichi AS. Characterization and comparison of poly (adenosine diphosphoribose) synthesis and DNA synthesis in nucleotide-permeable cells. Biochim Biophys Acta. 1978;519:87–104.Google Scholar
  2. Biedler JL. Drug resistance: genotype versus phenotype. Thirtysecond G.H.A. Clowes memorial award lecture. Cancer Res. 1994;54:666–78.Google Scholar
  3. Boulikas T. Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) (review). Anticancer Res. 1991;11:489–28.Google Scholar
  4. Chabert MG, Kopp PC, Bischoff PL, Mandel P. Cell culture of tumors alters endogenous poly(ADPR) polymerase expression and activity. Int J Cancer. 1993;53:837–42.Google Scholar
  5. Chen G, Hutter KJ, Bullerdiek J, Zeller WJ. Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumor cell line. J Cancer Res Clin Oncol. 1991;117:539–42.Google Scholar
  6. Chen G, Waxman DJ. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. J Pharmacol Exp Ther. 1995; in press.Google Scholar
  7. Chen G, Waxman DJ. Role of cellular glutathione and glutathioneS-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem Pharmacol. 1994;47:1079–87.Google Scholar
  8. Chen G, Zeller WJ. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. J Cancer Res Clin Oncol. 1990;116:443–7.Google Scholar
  9. Chen G, Zeller WJ. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthione sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res. 1991;11: 2231–8.Google Scholar
  10. Chen G, Zeller WJ. Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo. Cancer Chemother Pharmacol. 1993;33:157–62.Google Scholar
  11. Chen G, Zeller WJ. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells. Anticancer Res. 1994;14:1462–8.Google Scholar
  12. de Graeff A, Slebos RJC, Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol. 1988;22:325–33.Google Scholar
  13. Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol. 1986;4:244–57.Google Scholar
  14. Eastmann A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact. 1987;61:241–8.Google Scholar
  15. Fujii R, Mutoh M, Sumizawa T, Chen ZS, Yoshimura A, Akiyama SI. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Natl Cancer Inst. 1994;86:1781–4.Google Scholar
  16. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton T, Anderson M. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89: 3070–4.Google Scholar
  17. Griffith O. Determination of glutathione and glutathione disulfide using glatathione reductase and 2-vinylpyridine. Anal Biochem. 1980;106:207–12,Google Scholar
  18. Hamilton TC, Winker MA, Kouie KG et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drugresistant and- sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 1985;34:2583–6.Google Scholar
  19. Hosking LK, Whelan RDH, Shellard SA, Bedford P, Hill BT. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumor cell lines. Biochem Pharmacol. 1990;40:1833–42.Google Scholar
  20. Hospers GAP, Meijer C, de Leij L, Uges DRA, Mulder NH, de Vries EGE. A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer. 1990;46:138–44.Google Scholar
  21. Hromas RA, Andrews PA, Murphy MP, Burns CP. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett. 1987;34:9–13.Google Scholar
  22. Ishikawa T, Wright CD, Ishizuka H. GS-X pump is functionally overexpressed incis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem. 1994;269:29085–93.Google Scholar
  23. Marini M, Frabetti F, Brunelli A, Raggi MA. Inhibition of poly(ADP-ribose) polymerization preserves the glutathione pool and reverses cytotoxicity in hydrogen peroxide-treated lymphocytes. Biochem Pharmacol. 1993;46:2139–44.Google Scholar
  24. Meister A. Novel drugs that affect glutathione metabolism. In: Woolley PV III, Tew KD, eds. New York: Academic Press; 1988:99–126.Google Scholar
  25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods. 1983;65:55–65.Google Scholar
  26. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenesis and therapeutic agents. Cancer Res. 1990;50: 6119–29.Google Scholar
  27. Rosenberg B. Fundamental studies with cisplatin. Cancer. 1985;55:2302–16.Google Scholar
  28. Timmer-Bosscha H, Mulder NH, de Vries EGE. Modulation ofcis-diammine dichloroplatinum(II) resistance: a review. Br J Cancer. 1992;66:227–38.Google Scholar
  29. Worton RG, Duff C. Karyotyping. Cell Culture Methods Enzymol. 1979;58:322–440.Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • G. Chen
    • 1
  • K. -J. Hutter
    • 1
  • W. J. Zeller
    • 1
  1. 1.Forschungsschwerpunkt Diagnostik und Experimentelle TherapieDeutsches KrebsforschungszentrumHeidelbergGermany

Personalised recommendations